Search for stocks /

Metropolis Healthcare Q2 FY26 Concall Decoded – Clean Tests, Dirty Margins, and a Dose of AI Hope

1. Opening Hook
When your annual health check-up costs less than your cab ride to the lab, you know competition’s gone viral. πŸ§ͺ Amid price wars and post-pandemic malaise, Metropolis somehow pulled a 23% revenue growth β€” and still had breath left to brag about AI chatbots and β€œgenomic synergies.” Chairman Ameera Shah called it β€œsteady growth,” but it felt more like a well-timed caffeine rush. With B2C at 59% and Core Diagnostics integration still in ICU, the company’s trying to prove it’s not just another blood test factory. Stick around β€” this call had more tech talk than a startup pitch.


2. At a Glance

  • Revenue up 23%: Doctors’ prescriptions may slow, but Metropolis didn’t skip its growth meds.
  • EBITDA Margin 25.4%: Healthy, though Core Diagnostics’ weaker pulse pulled averages down.
  • PAT β‚Ή53 crore (up 13.6%): Profits jogged, didn’t sprint.
  • Organic EBITDA Margin 26.8%: 60 bps lift β€” efficiency is apparently the new multivitamin.
  • B2C share 59%: Consumers still bleeding for convenience.
  • Stock? Traders smiled β€” β€œAI-led diagnostics” sounded futuristic enough.

3. Management’s Key Commentary

Ameera Shah: β€œWe are building a resilient, future-ready diagnostics company.”
(Translation: We’ve said this for five years, but this time we’ve added AI.) 😏

Surendran Chemmenkotil: β€œMargins improved by 60 bps YoY to 26.8%.”
(Translation: We’ve upgraded from mild anemia to stable vitals.)

Sameer Patel: β€œCore Diagnostics moved from breakeven to high-single-digit margins.”
(Translation: Still in rehab, but at least the patient’s breathing.)

Ameera Shah: β€œNo new acquisitions for 6–9 months; focus on organic growth.”
(Translation: Wallet says stop, strategy says spin it as discipline.)

Surendran: β€œAdded 200 new centres, 300 more coming.”
(Translation: When in doubt, expand faster than your margins.)

Ameera Shah: β€œWe’re integrating AI for productivity and customer experience.”
(Translation: The robots can’t draw blood yet, but they can schedule your test politely.)

Ameera Shah: β€œOur moat is quality, accessibility and empathy.”
(Translation: The moat’s still being dug, but at least the PR’s ready.)


4. Numbers Decoded

Source table
MetricQ2 FY26YoY GrowthComment
Revenue (Group)β‚Ή429 Cr+23%Strong mix of TruHealth, Specialty, and mild fever season help.
EBITDA Margin (Group)25.4%Flat-ishCore Diagnostics dilution drags.
EBITDA Margin (Organic)26.8%+60 bps
Continue reading with a premium membership.
Become a member
error: Content is protected !!